Autoinflammation and autoimmunity: Bridging the divide

Autoimmunity Reviews

Volumn 12, Issue 1, 2012, Pages 22-30

  Doria, A ^a   Zen, M ^a   Bettio, S ^a   Gatto, M ^a   Bassi, N ^a   Nalotto, L ^a   Ghirardello, A ^a   Iaccarino, L ^a   Punzi, L ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autoantibodies; Autoimmune diseases; Autoinflammatory diseases; Innate immunity; Interleukin 1

Indexed keywords

ALPHA INTERFERON; AUTOIMMUNE REGULATOR PROTEIN; BETA INTERFERON; INFLAMMASOME; INTERLEUKIN 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ADRENAL INSUFFICIENCY; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOINFLAMMATORY DISEASE; CINCA SYNDROME; CLINICAL FEATURE; COLD EXPOSURE; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOPENIA; DERMATITIS; DISEASE ASSOCIATION; ECZEMA; ENDOCRINE DISEASE; ENTERITIS; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS; HYPERGAMMAGLOBULINEMIA; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; HYPOPARATHYROIDISM; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTRACELLULAR SIGNALING; IPEX SYNDROME; KIDNEY DISEASE; LYMPHADENOPATHY; MUCOCUTANEOUS CANDIDIASIS; ONSET AGE; PAPA SYNDROME; POLYENDOCRINOPATHY; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SMOKING; SPLENOMEGALY; STRESS; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GENETIC PREDISPOSITION TO DISEASE; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES;

EID: 84866851735     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.07.018     Document Type: Review

References (107)

1. Galeazzi M., Gasbarrini G., Ghirardello A., Grandemange S., Hoffman H.M., Manna R., et al. Autoinflammatory syndromes. Clin Exp Rheumatol 2006, 24:S79-S85.
2. Touitou I., Koné-Paut I. Autoinflammatory diseases. Best Pract Res Clin Rheumatol 2008, 22:811-829.
3. Farasat S., Aksentijevich I., Toro J.R. Autoinflammatory diseases. Clinical and genetic advances. Arch Dermatol 2008, 144:392-402.
4. Theofilopoulos A.N., Gonzalez-Quintial R., Lawson B.R., Koh Y.T., Stern M.E., Kono D.H., et al. Sensors of the innate immune system: their link to rheumatic diseases. Nat Rev Rheumatol 2010, 6:146-156.
5. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
6. McGonagle D., Sinisa S., McDermott M.F. The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation. Semin Immunopathol 2007, 29:303-313.
7. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
8. Kawasaki T., Kawai T., Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev 2011, 243:61-73.
9. Shinkai K., McCalmont T.H., Leslie K.S. Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 2008, 33:1-9.
10. Aksentijevich I, Putnam C., Remmers E.F., Mueller J.L., Le J., Kolodner R.D., et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56:1273-1285.
11. Faustin B., Reed J.C. Sunburned skin activates inflammasomes. Trends Cell Biol 2008, 18:4-8.
12. Lamkanfi M., Walle L.V., Kanneganti T.D. Deregulated inflammasome signaling in disease. Immunol Rev 2011, 243:163-173.
13. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010, 10:89-102.
14. Chung Y., Chang S.H., Martinez G.J., Yang X.O., Nurieva R., Kang H.S., et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
15. Masters S.L., Somin A., Aksentijevich I., et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory diseases. Annu Rev Immunol 2009, 27:621-668.
16. Aksentijevich I., Masters S.L., Ferguson P.J., Kastner D.L. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009, 360:2426-2437.
17. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
18. Allantaz F., Chaussabel D., Stichweh D., Punaro M., Bennett L., Allma W., et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007, 204:2131-2144.
19. Gül A. Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005, 4:81-83.
20. Feder H.M., Salazar J.C. A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr 2010, 99:178-184.
21. Kisand K., Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: known and novel aspects of the syndrome. Ann N Y Acad Sci 2011, 1246:77-91.
22. Torgerson T.R., Ochs H.D. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007, 120:744-750.
23. Worth A., Thrasher A.J., Gaspar H.B. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 2006, 133:124-140.
24. Cho J.H., Gregersen P.K. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011, 365:1612-1623.
25. Pontillo A., Girardelli M., Kamada A.J., Pancotto J.A., Donadi E.A., Crovella S., et al. Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 2012, 45:271-278.
26. Pétrilli V., Dostert C., Muruve D.A., Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007, 19:615-622.
27. Sfriso P., Ghirardello A., Botsios C., Tonon M., Zen M., Bassi N., et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 2010, 87:385-395.
28. Doria A., Zampieri S., Sarzi-Puttini P. Exploring the complex relationships between infections and autoimmunity. Autoimmun Rev 2008, 8:89-91.
29. Shoenfeld Y., Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
30. Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol 2009, 5:648-652.
31. Bassi N., Luisetto R., Del Prete D., Ghirardello A., Ceol M., Rizzo S., et al. Induction of the 'ASIA' syndrome in NZB/NZWF1 mice after injection of complete Freund's adjuvant (CFA). Lupus 2012, 21:203-209.
32. Atzeni F., Turiel M., Capsoni F., Doria A., Meroni P., Sarzi-Puttini P. Autoimmunity anti-TNFα agents. Ann N Y Acad Sci 2005, 1051:559-569.
33. Kastner D.L., Aksentijevich K.I., Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010, 140:784-790.
34. Sarzi-Puttini P., Atzeni F., Iaccarino L., Doria A. Environment and systemic lupus erythematosus: an overview. Autoimmunity 2005, 38:465-472.
35. Doria A., Sherer Y., Meroni P.L., Shoenfeld Y. Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 2005, 31:355-362.
36. Stojanovich L. Stress and autoimmunity. Autoimmun Rev 2010, 9:271-276.
37. Cooper G.S., Stroehla B.C. The epidemiology of autoimmune diseases. Autoimmun Rev 2003, 2:119-125.
38. Pelagatti M.A., Meini A., Caorsi R., Cattalini M., Federici S., Zulian F., et al. Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 2011, 63:1141-1150.
39. Govoni M., Bombardieri S., Bortoluzzi A., Caniatti L., Casu C., Conti F., et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology 2012, 51:157-168.
40. Briani C., Lucchetta M., Ghirardello A., Toffanin E., Zampieri S., Ruggero S., et al. Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun 2009, 32:79-84.
41. Doria A., Iaccarino L., Sarzi-Puttini P., Atzeni F., Turriel M., Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus 2005, 14:683-686.
42. Kiefer C., Cribier B., Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine 2009, 88:23-31.
43. Bano S., Bombardieri S., Doria A., Iaccarino L., Lehmann P., Mosca M. Lupus erythematosus and the skin. Clin Exp Rheumatol 2006, 24:S26-S35.
44. Drenth J.P., Boom B.W., Toonstra J., Van der Meer J.W. Cutaneous manifestations and histologic findings in hyper-immunoglobulin D syndrome. International Hyper IgD Study Group. Arch Dermatol 1994, 130:59-65.
45. Lamprecht P., Moosig F., Adam-Klages S., Mrowietz U., Csernok E., Kirrstetter M., et al. Small vessel vasculitis and relapsing panniculitis in tumor necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2004, 63:1518-1520.
46. Barzili A., Langevitz P., Goldberg I., Kopolovic J., Livneh A., Pras M., et al. Erysipelas-like erythema of familial Mediterranean fever: clinical-pathologic correlation. J Am Acad Dermatol 2000, 42:791-795.
47. Prieur A.M., Griscelli C., Lampert F., Truckenbrodt H., Guggenheim M.A., Lovell D.J., et al. A chronic, infantile, neurologic, cutaneous and articular (CINCA) syndrome. A specific entity analyzed in 30 patients. Scand J Rheumatol Suppl 1987, 66:57-68.
48. Lee J.Y., Yang C.C., Hsu M.M. Histopathology of persistent papules and plaques in adult-onset Still's disease. J Am Acad Dermatol 2005, 52:1003-1008.
49. Yanagawa H., Nakamura Y., Yashiro M. Results of 16 nationwide surveys of Kawasaki disease in Japan. Acta Pediatr Jpn 2002, 65:332-342.
50. Padeh S., Brezniak N., Zemer D., Pras E., Livneh A., Langevitz P., et al. Periodic fever, aphthous stomatitis, pharyngitis and adenopathy syndrome: clinical characteristic and outcome. J Pediatr 1999, 135:98-101.
51. Uthman I., EI-Sayyad J., EI-Jajj I., Bizri A.R., et al. Familial Mediterranean fever mimicking septic arthritis. Rheumatol Int 2005, 25:633-634.
52. Obici L., Merlini G. Amyloidosis in autoinflammatory syndromes. Autoimm Rev 2012, 12(1):14-17. (this issue).
53. Briani C., Doria A., Sarzi-Puttini P., Dalakas M.C. Update on idiopathic inflammatory myopathies. Autoimmunity 2006, 39:161-170.
54. Thacker P.G., Binkovitz L.A., Thomas K.B. Deficiency of interleukin-1-receptor antagonist syndrome: a rare auto-inflammatory condition that mimics multiple classic radiographic findings. Pediatr Radiol 2012, 42:495-498.
55. Gattorno M., Federici S., Pelagatti M.A., Caorsi R., Brisca G., Malattia C., et al. Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol 2008, 28:S73-S83.
56. Ebert E.C., Hagspiel K.D. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 2011, 45:436-441.
57. Doria A., Bonavina L., Anselmino M., Ruffatti A., Favaretto M., Gambari P., et al. Esophageal involvement in mixed connective tissue disease. J Rheumatol 1991, 18:685-690.
58. Anselmino M., Zaninotto G., Costantini M., Ostuni P., Ianniello A., Boccú C., et al. Esophageal motor function in primary Sjögren's syndrome: correlation with dysphagia and xerostomia. Dig Dis Sci 1997, 42:113-118.
59. Uttenthal B.J., Layton D.M., Vyse T.J., Schreiber B.E. The wolf at the door. N Engl J Med 2012, 366:2216-2221.
60. Di Pietra L., Gardiman M., Terranova C. Postpartum maternal death associated with undiagnosed Hodgkin's lymphoma. Med Sci Law 2012, 52(3):174-177.
61. Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. Clin Exp Rheumatol 2011, 29:850-857.
62. Obici L., Raimondi S., Lavatelli F., Bellotti V., Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009, 61:1435-1440.
63. Riera E., Olivé A., Narváez J., Holgado S., Santo P., Mateo L., et al. Adult onset Still's disease: review of 41 cases. Clin Exp Rheumatol 2011, 29:331-336.
64. Zandman-Goddard G., Orbach H., Agmon-Levin N., et al. Hyperferritinemia is Associated with Serologic Antiphospholipid Syndrome in SLE Patients. Clin Rev Allergy Immunol Mar 11 2011, 11. http://dx.doi.org/10.1007/s12016-011-8264-0 [Electronic publication ahead of print].
65. Kallinich T., Wittkowski H., Keitzer R., Roth J., Foell D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis 2010, 69:677-682.
66. Zen M., Bassi N., Nalotto L., Canova M., Bettio S., Gatto M., et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol Jul 5 2012, PMID: 22765883 [Electronic publication ahead of print].
67. Ghirardello A., Villalta D., Morozzi G., et al. Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. Clin Exp Rheumatol 2011, 29:50-56.
68. Ghirardello A., Villalta D., Morozzi G., Afeltra A., Galeazzi M., Gerli R., et al. Evaluation of current methods for the measurement of serum anti-double-stranded DNA antibodies. Ann N J Acad Sci 2007, 1109:401-406.
69. Villata D., Romelli P.B., Savina C., Bizzaro N., Tozzoli R., Tonutti E., et al. Anti-dsDNA antibody avidità determination by simple reliable ELISA method for SLE diagnosis and monitoring. Lupus 2003, 12:31-36.
70. Ghirardello A., Doria A., Zampieri S., Tarricone E., Tozzoli R., Villalta D., et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun 2004, 22:235-240.
71. Ghirardello A., Bendo R., Rampudda M.E., Bassi N., Zampieri S., Doria A. Commercial blot assays in the diagnosis of systemic rheumatic diseases. Autoimmun Rev 2009, 8:645-649.
72. Zampieri S., Mahler M., Blüthner M., Qiu Z., Malmegrim K., Ghirardello A., et al. Recombinant anti-P proteins autoantibodies isolated from a human autoimmune library: reactivity, specificity and epitope recognition. Cell Mol Life Sci 2003, 60:588-598.
73. Ghirardello A., Caponi L., Franceschini F., Zampieri S., Quinzanini M., Bendo R., et al. Diagnostic tests for antiribosomal P protein antibodies: a comparative evaluation of immunoblotting and ELISA assays. J Autoimmun 2002, 19:71-77.
74. Zampieri S., Degen W., Ghirardello A., Doria A., van Venrooij W.J. Dephosphorylation of autoantigenic ribosomal P proteins during FAS-L induced apoptosis; a possible trigger for the development of the autoimmune response in SLE patients. Ann Rheum Dis 2001, 60:72-76.
75. Ghirardello A., Doria A., Zampieri S., Gerli R., Rapizzi E., Gambari P.F. Anti ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with the IgG anticardiolipin antibodies. Ann Rheum Dis 2000, 59:975-981.
76. Bartoloni E., Alunno A., Bistoni O., Bizzaro N., Migliorini P., Morozzi G., et al. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev Feb 27 2012, http://dx.doi.org/10.1016/j.autrev.2012.02.015 [Electronic publication ahead of print].
77. Bizzaro N., Allegri F., Alpini C., Doria A., Gerli R., Lotzniker M., et al. Assay to detect antiviral citrullinated peptide antibodies: a collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni. J Clin Pathol 2011, 64:1139-1141.
78. Iaccarino L., Ghirardello A., Canova M., Zen M., Bettio S., Nalotto L., et al. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev 2011, 10:553-558.
79. Bizzarro N., Ghirardello A., Zampieri S., Iaccarino L., Tozzoli R., Ruffatti A., et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007, 5:1158-1164.
80. Ghirardello A., Doria A., Ruffatti A., Rigoli A., Vesco P., Calligaro A., et al. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE). Are they specific tools for the diagnosis of aPL syndrome in SLE?. Ann Rheum Dis 1994, 53:140-142.
81. Ghirardello A., Doria A., Vesco P., Vaccaro E., Bernardi C., Catani C., et al. Blotting pattern of IgG Anti-(U1)RNP antibodies in mixed connective tissue disease. Rheumatol Int 1996, 16:145-150.
82. Ghirardello A., Rampudda M., Ekholm L., Bassi N., Tarricone E., Zampieri S., et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 2010, 49:2370-2374.
83. Ghirardello A., Zampieri S., Tarricone E., Iaccarino L., Gorza L., Doria A., Tarricone E. Cutting edge issues in polymyositis. Clin Rev Allergy Immunol 2011, 41:179-189.
84. Ghirardello A., Zampieri S., Tarricone E., Iaccarino L., Bendo R., Briani C., et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 2006, 39:217-221.
85. Zampieri S., Ghirardello A., Iaccarino L., Tarricone E., Gambari P.F., Doria A. Anti-JO-1 antibodies. Autoimmunity 2005, 38:73-78.
86. Ghirardello A., Zampieri S., Iaccarino L., Tarricone E., Bendo R., Gambari P.F., et al. Anti-MI-2 antibodies. Autoimmunity 2005, 38:79-83.
87. Hengstman G.J., Vree Egberts W.T., Seelig H.P., Lundberg I.E., Moutsopoulos H.M., Doria A., et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen. Ann Rheum Dis 2006, 65:242-245.
88. Rekvig O.P., Putterman C., Casu C., Gao H.X., Ghirardello A., Mortensen E.S., et al. Autoantibodies in lupus: culprits or passive bystanders?. Autoimmun Rev 2012, 11:596-603.
89. Bassi N., Ghirardello A., Blank M., Zampieri S., Sarzi-Puttini P., Mantovani A., et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010, 69:1704-1710.
90. Goldbach-Mansky R. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 2012, 167:391-404.
91. Lachmann H.J., Quartier P., So A., Hawkins P.N. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum 2011, 63:314-324.
92. Higgs B.W., Zhu W., Richman L., Fiorentino D.F., Greenberg S.A., Jallal B., et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 2012, 15:25-35.
93. Doria A., Ghirardello A., Iaccarino L., Zampieri S., Punzi L., Tarricone E., et al. Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum 2004, 51:989-995.
94. Doria A., Cutolo M., Ghirardello A., Zen M., Villalta D., Tincani A., et al. Effect of pregnancy on serum cytokines in SLE patients. Arthritis Res Ther 2012, 14:R66.
95. Zen M., Canova M., Campana C., Bettio S., Nalotto L., Rampudda M., et al. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011, 10:305-310.
96. Bhat A., Naguwa S.M., Cheema G.S., Gershwin M.E. Colchicine revisited. Ann N Y Acad Sci 2009, 1173:766-773.
97. Doria A., Zen M., Canova M., Bettio S., Bassi N., Nalotto L., et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010, 10:55-60.
98. Shugaiv E., Tüzün E., Mutlu M., Kiyat-Atamer A., Kurtuncu M., Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol 2011, 29:S64-S67.
99. Iaccarino L., Rampudda M., Canova M., Della Libera S., Sarzi-Puttinic P., Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?. Autoimmun Rev 2007, 6:190-195.
100. Chevrel G., Jenvrin C., McGregor B., Miossec P. Renal type AA amyloidosis associated with heumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology (Oxford) 2001, 40:821-825.
101. Geyer M., Müller-Ladner U. Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol 2010, 22:246-251.
102. Caorsi R., Federici S., Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev 2012, 12(1):81-86. (this issue).
103. Ballanti E., Perricone C., di Muzio G., Kroegler B., Chimenti M.S., Graceffa D., et al. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev 2011, 10:617-623.
104. Rosenblum H., Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011, 10:563-568.
105. Olivieri I., Sarzi-Puttini P., Bugatti S., Atzeni F., d'Angelo S., Caporali R. Early treatment in early undifferentiated arthritis. Autoimmun Rev 2012, 11:589-592.
106. Buch M.H., Rubbert-Roth A., Ferraccioli G. To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. Autoimmun Rev 2012, 11:558-562.
107. Atzeni F., Sarzi-Puttini P., Gorla R., Marchesoni A., Caporali R. Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 2011, 10:397-403.